• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    9/18/23 1:31:11 PM ET
    $AVGR
    $CATX
    $EVAX
    $LIFW
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AVGR alert in real time by email

    Gainers

    • Avinger (NASDAQ:AVGR) shares rose 79.6% to $7.43 during Monday's regular session. Trading volume for this security as of 13:30 EST is 32.7 million, which is 413861.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.3 million.
    • Perspective Therapeutics (AMEX:CATX) stock rose 46.34% to $0.3. Perspective Therapeutics's stock is trading at a volume of 37.4 million shares as of 13:30 EST. This is 11801.4% of its average full-day volume over the last 100 days. The company's market cap stands at $84.1 million.
    • SCWorx (NASDAQ:WORX) stock moved upwards by 44.89% to $0.27. Trading volume for this security as of 13:30 EST is 106.3 million, which is 1880.9% of its average full-day volume over the last 100 days. The company's market cap stands at $4.5 million.
    • T2 Biosystems (NASDAQ:TTOO) stock moved upwards by 42.38% to $0.39. Trading volume for T2 Biosystems's stock is 259.4 million as of 13:30 EST. This is 242.8% of its average full-day volume over the last 100 days. The company's market cap stands at $131.6 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) shares increased by 36.51% to $4.33. As of 13:30 EST, this security is trading at a volume of 2.6 million shares, making up 3611.8% of its average full-day volume over the last 100 days. The company's market cap stands at $63.8 million. The company's, Q2 earnings came out yesterday.
    • SeqLL (NASDAQ:SQL) stock increased by 33.68% to $17.7. As of 13:30 EST, SeqLL's stock is trading at a volume of 2.7 million, which is 13728.5% of its average full-day volume over the last 100 days. The company's market cap stands at $6.7 million.

    Losers

    • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) stock fell 62.1% to $0.0 during Monday's regular session. Trading volume for this security as of 13:30 EST is 1.6 million, which is 303.0% of its average full-day volume over the last 100 days.
    • MSP Recovery (NASDAQ:LIFW) stock fell 37.77% to $0.12. The current volume of 54.8 million shares is 450.0% of MSP Recovery's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $38.8 million.
    • Strata Skin Sciences (NASDAQ:SSKN) stock decreased by 32.7% to $0.67. Trading volume for Strata Skin Sciences's stock is 134.0K as of 13:30 EST. This is 96.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $23.4 million.
    • Evaxion Biotech (NASDAQ:EVAX) stock declined by 20.23% to $0.6. Trading volume for this security as of 13:30 EST is 279.2K, which is 489.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.5 million.
    • Senti Biosciences (NASDAQ:SNTI) stock fell 19.06% to $0.47. Senti Biosciences's stock is trading at a volume of 82.7K shares as of 13:30 EST. This is 111.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.9 million.
    • UpHealth (NYSE:UPH) shares declined by 16.26% to $1.0. Trading volume for UpHealth's stock is 285.9K as of 13:30 EST. This is 739.7% of its average full-day volume over the last 100 days. The company's market cap stands at $17.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVGR
    $CATX
    $EVAX
    $LIFW

    CompanyDatePrice TargetRatingAnalyst
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Perspective Therapeutics Inc.
    $CATX
    2/19/2026$16.00Overweight
    Piper Sandler
    Perspective Therapeutics Inc.
    $CATX
    11/24/2025$12.00Buy
    Truist
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    Perspective Therapeutics Inc.
    $CATX
    10/10/2025$14.00Buy
    BTIG Research
    Senti Biosciences Inc.
    $SNTI
    6/6/2025$5.00Buy
    Laidlaw
    Perspective Therapeutics Inc.
    $CATX
    3/13/2025$10.00Buy
    H.C. Wainwright
    Perspective Therapeutics Inc.
    $CATX
    3/7/2025$15.00Sector Outperform
    Scotiabank
    More analyst ratings

    $AVGR
    $CATX
    $EVAX
    $LIFW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres. & Chief Med. & Dev. Off. Rajangam Kanya covered exercise/tax liability with 10,757 shares (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    3/11/26 4:01:55 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO Lu Timothy K covered exercise/tax liability with 80,666 shares (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    3/11/26 4:01:30 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Martinez Maria E

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    3/4/26 4:38:30 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $AVGR
    $CATX
    $EVAX
    $LIFW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Perspective Therapeutics with a new price target

    Piper Sandler initiated coverage of Perspective Therapeutics with a rating of Overweight and set a new price target of $16.00

    2/19/26 7:52:02 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Truist resumed coverage on Perspective Therapeutics with a new price target

    Truist resumed coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $12.00

    11/24/25 9:17:24 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $AVGR
    $CATX
    $EVAX
    $LIFW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

    Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoingData across all dose levels in the VMT-α-NET program provide development optionality and support the build-out of a robust clinical evidence package for submission for presentation to more medical conferences and regulatory engagement in 2026Clinical updates for all three clinical programs are expected to be submitted f

    3/16/26 4:07:00 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Evaxion announces business update and full year 2025 financial results

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces full year 2025 financial results. Business highlights2025 was a transformational year for Evaxion with significant strengthening of our fundamental business both strategically, scientifically and financially through achievement of several milestones. Highlights include: The historic licensing of our infectious disease vaccine candidate EVX-B3 by MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA)Unprecedented two-year phase 2 data for our personalized cancer vaccine candid

    3/5/26 9:28:15 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion plans to file 2025 annual report later today

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.   The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself.  As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E

    3/5/26 8:02:13 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVGR
    $CATX
    $EVAX
    $LIFW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rubinstein Samuel sold $18,804 worth of shares (14,094 units at $1.33) and bought $7,028 worth of shares (5,000 units at $1.41), decreasing direct ownership by 51% to 8,766 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    11/18/25 4:35:42 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/17/25 8:01:56 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/14/25 8:00:03 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $AVGR
    $CATX
    $EVAX
    $LIFW
    SEC Filings

    View All

    SEC Form 10-K filed by Perspective Therapeutics Inc.

    10-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    3/16/26 4:12:49 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    3/16/26 4:10:36 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    3/5/26 9:42:14 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVGR
    $CATX
    $EVAX
    $LIFW
    Leadership Updates

    Live Leadership Updates

    View All

    Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

    Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion's strategy Birgitte Rønø, who has served as interim Chief Executive Officer, will continue in her role as Chief Scientific OfficerSeasoned life science executive Jens Bitsch-Norhave will join as observer and advisor to the Board of Directors with the intention of seeking election at the

    10/27/25 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SCWorx Corp. Appoints New Chief Technology Officer to Accelerate Innovation in Healthcare Data Solutions

    Tampa, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:WORX), a leading provider of data management and software solutions for the healthcare industry, today announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx's commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the developm

    9/3/25 11:44:49 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AVGR
    $CATX
    $EVAX
    $LIFW
    Financials

    Live finance-specific insights

    View All

    Evaxion plans to file 2025 annual report later today

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.   The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself.  As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E

    3/5/26 8:02:13 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET. A webcast replay will be available on the Events page of the Investors section of the Company's website (sentibio.com). Interested parties may access the live video webcast here. About Senti Bio Senti Bio is a biotechnolog

    3/3/26 9:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to announce business update and full year 2025 financial results on March 5, 2026

    COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces

    3/2/26 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVGR
    $CATX
    $EVAX
    $LIFW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care